Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies United Kingdom

Zonisamide Zooms Up In October

Pricewatch UK – October 2020

  • Data

Executive Summary

Zonisamide presentations saw average price increases of as much as five times in October, according to the latest UK figures from WaveData.

You may also be interested in...



Olmesartan Prices Treble In UK

Average UK trade prices of olmesartan as much as trebled across multiple presentations in the second month of 2021. However, this was not the only triple-digit price rise seen during February, WaveData reveals.

Exemestane Prices Tumble As UK Sees Reductions

Exemestane 25mg tablets saw their average UK trade price drop by a third in November, according to the latest figures from WaveData.

Ciprofloxacin Garners No UK Concessions Despite Rises

Despite the average trade price of ciprofloxacin shooting up in September, no UK price concessions were granted by the DHSC.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies United Kingdom
Latest News

What’s Next? Five Things To Look Out For In October

Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment

Glenmark’s Ryaltris Set To Hit Canadian Market

Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs

See All
UsernamePublicRestriction

Register

GB150428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By